Skip to content
2000
Volume 15, Issue 6
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/138920101506140910145940
2014-06-01
2025-07-04
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/138920101506140910145940
Loading

  • Article Type:
    Research Article
Keyword(s): Biologics; dermatomyositis; interstitial lung disease; polymyositis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test